GNAO1 encephalopathy

What GNAO1 encephalopathy is

GNAO1 encephalopathy was first described as a genetic cause of early infantile epileptic encephalopathy in 2013, and has since been recognised as one of the more common single-gene causes of childhood-onset chorea–dystonia syndromes. The clinical picture varies more than for many other genetic encephalopathies: some children present mainly with seizures, others almost exclusively with a movement disorder, and many sit between the two.

Across all presentations, the developmental impact is usually severe and the movement disorder is often the most disabling daily problem — and the most dangerous, because of the risk of status dystonicus.

The genetic cause (GNAO1)

GNAO1 makes Gαo, the alpha subunit of an inhibitory G-protein that is heavily expressed in the basal ganglia and cortex. G-proteins act as molecular switches passing signals from receptors at the cell surface into the cell, so a faulty Gαo subunit disturbs how neurons respond to neurotransmitters that shape both excitability (seizures) and movement (basal-ganglia output).

Almost all variants are new in the child (de novo). The recurrence risk in a future pregnancy is very low unless a parent carries the change in a small proportion of their cells (mosaicism). Variants tend to cluster in particular regions of the protein, and certain specific changes (for example R209H, G203R, E246K) are recurrent and associated with characteristic clinical patterns.

How it presents

• Seizures starting in the first weeks to months of life — focal, tonic, or epileptic spasms (West syndrome) are most common in the epilepsy-predominant picture
• Severe global developmental delay; most affected children are non-verbal and require help with all daily activities
• Movement disorder is the defining feature for many children: chorea (constant rapid involuntary movements), dystonia (sustained twisting postures), ballism (large flinging movements), or a mixed picture; dyskinesia is often worse with stress, illness or sleep deprivation
• Status dystonicus — sustained, severe dyskinesia that prevents rest and can cause exhaustion, rhabdomyolysis and metabolic crisis — is a recognised paediatric neurology emergency in this condition
• Hypotonia early on, evolving into mixed tone with age; many children never walk independently
• Autonomic dysregulation, feeding and respiratory problems are common; some children require gastrostomy and ventilation support

Investigations and diagnosis

Diagnosis is made by detecting a heterozygous pathogenic GNAO1 variant — through a gene panel for early-onset epilepsy or movement disorder, chromosomal microarray (occasional deletions), or whole-exome / whole-genome sequencing. A movement-disorder-predominant child with severe early dyskinesia and no obvious metabolic cause should be tested for GNAO1, as the dyskinetic picture can sometimes be mistaken for cerebral palsy.

MRI is often normal or shows non-specific changes. EEG findings depend on the seizure phenotype. Genetic confirmation matters because it changes treatment thinking: certain medicines used routinely for movement disorders behave differently in GNAO1, and deep brain stimulation has a strong evidence base specifically in this condition.

Current management

Management is symptomatic and multidisciplinary: paediatric neurology, movement-disorder specialist, intensive-care expertise when status dystonicus occurs, physiotherapy and occupational therapy, gastroenterology and respiratory input. The single biggest priority in many children is preventing and treating dyskinetic crises.

• Seizures are managed with standard antiseizure medicines guided by seizure type; the ketogenic diet has helped in some cases
• For chorea and dyskinesia: tetrabenazine, gabapentin, clonazepam, and trihexyphenidyl are common first lines; the response varies between children
• Deep brain stimulation of the globus pallidus interna (GPi-DBS) has the strongest evidence base for severe movement disorder in GNAO1 — published case series show meaningful improvement in many children, often striking, and DBS should be considered early when the movement disorder is disabling or recurrent status dystonicus occurs
• Status dystonicus is a neurological emergency: it requires high-dependency or intensive-care management with sedation, attention to airway, hydration, electrolytes and rhabdomyolysis prevention; teams familiar with the condition manage it best
• Standard developmental, communication and gastrostomy/nutrition support; AAC is central

The research pipeline: first allele-specific ASO in trial

GNAO1 encephalopathy is one of the first ultra-rare neurogenetic conditions where allele-specific antisense oligonucleotide (ASO) therapy has reached the clinic. The biological rationale is clean: because most pathogenic variants act as gain-of-function or dominant-negative changes, silencing the mutant allele while leaving the healthy one alone should restore function — and this can in principle be tailored to a specific variant. All programmes below remain investigational.

• Tianasen (ASO-GNAO1) — an open-label, non-randomised Phase 1/2 study of an antisense oligonucleotide for GNAO1 encephalopathy began enrolling in September 2025, with completion expected by the end of 2026 (ClinicalTrials.gov NCT07363603). It is one of the first allele-specific ASO trials in any neurogenetic condition.
• Personalised allele-specific ASOs — academic groups (including via the n-Lorem Foundation) are developing variant-tailored ASOs as individual nano-rare therapies for specific GNAO1 mutations.
• AAV-RNAi gene therapy — preclinical work has reported reduction in hyperlocomotion and dystonic features in GNAO1 mutant mice; programmes are progressing through IND-enabling studies.
• Family-led research and registries — the Bow Foundation (Building Outcomes for Children with GNAO1 Worldwide) runs a natural-history programme and supports several of the therapeutic programmes above.

How an educational review can help

If your child has — or might have — GNAO1 encephalopathy, an educational review can summarise what is known about the specific variant, organise the seizure and movement-disorder picture, explain the role of DBS and the current ASO programme, and outline an escalation plan for dyskinetic crises with your treating team. It is educational and supports — never replaces — your clinicians.